dm+d

45844004

Articles

Safety in lactation: Drugs for chronic bowel disorders

21 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Aminosalicylates for chronic bowel disorders Mesalazine…

What medicines should be avoided by patients suffering from “sulfa allergy”?

12 June 2020This updated Medicines Q&A evaluates the limited evidence available on cross-sensitivity between sulfonamide-containing medicines and lists classes of medication that contain a sulfonamide in their…
Search Articles

Medicine Compliance Aid Stability

Salazopyrin ENPharmacia Ltd

Pharmacia Ltd
Salazopyrin EN
Tablets e/c 500mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Store in airtight containers and protect from light.
22 October 2015

SalazopyrinPfizer Ltd

Pfizer Ltd
Salazopyrin
Tablets 500mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Airtight container
Protect from light
Store in airtight containers and protect from light.
22 October 2015

Salazopyrin ECPharmacia Ltd

Pharmacia Ltd
Salazopyrin EC
Tablets e/c 500mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light in well closed containers.
27 November 2015

SalazopyrinPharmacia Ltd

Pharmacia Ltd
Salazopyrin
Salazopyrin
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light in well closed containers.
27 November 2015

Lactation Safety Information

for inflammatory bowel disease

for inflammatory bowel disease
Mesalalzine
30 July 2020

for rheumatoid arthritis

for rheumatoid arthritis
See summary
Mesalazine, which is an active metabolite of sulfasalazine, has been associated with a small number of possible cases of diarrhoea in breastfed infants. An additional case of sulfasalazine-related bloody diarrhoea has also been reported
Its sulfapyridine metabolite presents a theoretical risk of neonatal haemolysis, especially in G6PD-deficient infants
Monitor infant for diarrhoea
30 July 2020